| Name | Title | Contact Details |
|---|
An individualized, trauma-sensitive, and holistic approach to addressing boys` emotional and behavioral issues, and educational, recreational, and vocational goals.
Les Restaurants Pacini is a La Prairie, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Albion Laboratories is a Clearfield, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Lenox Hill Hospital, a member of the North Shore-LIJ Health System, is a 652-bed, fully accredited, acute care hospital located on Manhattan’s Upper East Side with a national reputation for outstanding patient care and innovative medical and surgical treatments. US News and World Report has ranked the hospital among the nation’s top 50 in Cardiology and Heart Surgery and among the top 10 hospitals in the state of New York with a total of 11 “high performing” designations for its clinical performance in Cancer, Diabetes and Endocrinology, Ear, Nose and Throat, Gastroenterology and GI Surgery, Geriatrics, Gynecology, Nephrology, Neurology and Neurosurgery, Orthopedics, Pulmonology and Urology.
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.